Regeneron Pharmaceuticals (REGN) FCF Margin (2009 - 2026)

Regeneron Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 13.35% for Q2 2026.

• In Q2 2026, FCF Margin fell 1183.0% year-over-year to 13.35%; the TTM figure through Jun 2026 stood at 28.84% (down 138.0% YoY), while the FY2025 annual figure was 33.47%, up 341.0% from the prior year.
• FCF Margin for Q2 2026 stood at 13.35%, down from 23.53% in the prior quarter.
• The five-year high for FCF Margin was 3919.8% in Q1 2022, with the low at 9.48% in Q2 2024.
• The 5-year median for FCF Margin is 26.06% (2025), against an average of 329.32%.
• The sharpest annual moves came in 2022 and 2023: FCF Margin jumped 389632 bps in 2022, then tumbled 388219 bps in 2023.
• Regeneron Pharmaceuticals' FCF Margin stood at 1567.7% in 2022, then plunged by 98 bps to 24.41% in 2023, then jumped by 80 bps to 44.01% in 2024, then retreated by 4 bps to 42.26% in 2025, then tumbled by 68 bps to 13.35% in 2026.
• Business Quant data shows REGN's FCF Margin at 13.35% in Q2 2026, 23.53% in Q1 2026, and 42.26% in Q4 2025.